Big Data Investments in Healthcare & Pharma to Reach USD 4 Bn by 2017, States SNS Telecom in Its New Report Available at MarketPublishers.com16 Aug 2017 • by Natalie Aster
LONDON – In the midst of the proliferation of historical data and real-time data (RTD) from sources like connected devices, Internet, sensors, social media, log files and transactional apps, Big Data is gathering good momentum from a versatile scope of vertical sectors. In that vein, the healthcare and pharma sector constitutes no exception to this tendency, where Big Data has enjoyed manifold applications – from pharmaceutical research and personalised medicine to clinical decision support (CDS) and population health management (PHM).
The size of Big Data investments in the healthcare and pharma industry is projected to amount to close to USD 4 billion by end-2017. Going forward, driven by the existence of a slew of business opportunities for insurance firms, healthcare providers, payers, power structures, pharma firms, among others, these investments are poised to grow further at a CAGR of over 15% during the next 3 years.
The comprehensive research report “Big Data in the Healthcare & Pharmaceutical Industry: 2017 – 2030 – Opportunities, Challenges, Strategies & Forecasts” created by SNS Telecom presents an in-depth, trustworthy assessment of the Big Data in the healthcare and pharmaceutical ecosystem.
The research study examines major market trends, challenges, investment prospects, drivers and challenges, areas of applications, use cases, future development, value chain, as well as companies’ profiles alongside their strategies. The publication also presents projections of the market size for Big Data software, hardware, professional services investments during 2017-2030; with the forecast data categorised by 8 horizontal submarkets, 5 application fields, 36 use cases, 6 regions and 35 nations.
More new in-demand reports by the publisher are available at SNS Telecom page.